Puma Biotechnology, Inc., a development-stage biopharmaceutical company, engages in the acquisition, in-licensing, development, and commercialization of drug candidates for the treatment of various forms of cancer. Its products under development include PB272 (neratinib (oral)) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2) positive metastatic breast cancer and gastric cancer; and PB272 (neratinib (intravenous)) for the treatment of patients with advanced cancer. The company also focuses on developing PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor, which blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. Puma Biotechnology, Inc. has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and certain related compounds. The company was founded in 2010 and is headquartered in Los Angeles, California.